Author

Timothy P. Cripe

Nationwide Children's HospitalORCID 0000-0002-8595-3577Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

P Ralph· 2 shared Pin-Yi WangiD· 2 shared Tania L. WeissiD· 2 shared Tonny Johnson· 2 shared Amy C. GrossiD· 1 shared Andrea M. GlaspelliD· 1 shared Armin AhnoudiD· 1 shared Beth DiNello· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

P Ralph

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyJournal of Immunological MethodsPeer-reviewedNov 14, 2025

Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody

Tania L. Weiss, Justine Paniagua, Tonny Johnson…·P Ralph

The paper develops a GMP-compliant cell-based potency assay to measure the efficacy of GP101, a CD3-CD19 diabody, using fluorescence detection of T-cell mediated B-cell lysis.

DOI 10.1016/j.jim.2025.114004

humanproteomics

𝕏 PostBluesky

ImmunologybioRxivPreprintMar 19, 2025

Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti-CD19-AntiCD3 Diabody

Tonny Johnson, Armin Ahnoud, Beth DiNello…·Tania L. Weiss

The paper develops a sensitive GLP-compliant ELISA for detecting GP101 diabody in mouse serum, achieving 15pg/mL sensitivity.

1 citation

mouseproteomics

𝕏 PostBluesky

Cancer BiologyMolecular Therapy OncologyPeer-reviewedSep 26, 2024

Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma

Emily M. Ringwalt, Mark A. Currier, Andrea M. Glaspell…·Timothy P. Cripe

This study shows trabectedin enhances oncolytic virotherapy by reducing anti-viral barriers and boosting immune-mediated tumor regression in preclinical models.

9 citations

humanmouse

𝕏 PostBluesky